

## PRIOR AUTHORIZATION POLICY

**POLICY:** Oncology – Valchlor Prior Authorization Policy

- Valchlor® (mechlorethamine gel for topical use – Helsinn Therapeutics)

**REVIEW DATE:** 10/28/2020

---

### OVERVIEW

Valchlor, a nitrogen mustard, is indicated for the topical treatment of stage IA and IB **mycosis fungoides-type cutaneous T-cell lymphoma** in patients who have received prior skin-directed therapy.<sup>1</sup>

### Guidelines

The National Comprehensive Cancer Network (NCCN) guidelines for **primary cutaneous lymphomas** (version 1.2021 – October 12, 2020) recommend Valchlor for the topical treatment of primary cutaneous B-cell lymphoma, mycosis fungoides/Sezary syndrome, and primary cutaneous CD30+ T-cell lymphoproliferative disorders.<sup>2,3</sup>

The NCCN guidelines for **T-cell lymphomas** (version 1.2021 – October 5, 2020) recommends Valchlor for the topical treatment of adult T-cell leukemia/lymphoma – chronic/smoldering subtype.<sup>2,4</sup>

### POLICY STATEMENT

Prior authorization is recommended for prescription benefit coverage of Valchlor. All approvals are provided for the duration noted below.

**Automation:** None.

### RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Valchlor is recommended in those who meet the following criteria:

#### FDA-Approved Indications

1. **Cutaneous Lymphomas** Note: Includes mycosis fungoides/Sezary syndrome, primary cutaneous B-cell lymphoma, primary cutaneous CD30+ T-cell lymphoproliferative disorders. Approve for 3 years.

#### Other Uses with Supportive Evidence

2. **Adult T-Cell Leukemia/Lymphoma.** Approve for 3 years if the patient has chronic/smoldering subtype of adult T-cell leukemia/lymphoma.

### CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Valchlor is not recommended in the following situations:

1. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

### REFERENCES

## Oncology – Valchlor PA Policy

### Page 2

1. Valchlor<sup>®</sup> gel [prescribing information]. Iselin, NJ: Helsinn Therapeutics; January 2020.
2. The NCCN Drugs and Biologics Compendium. © 2020 National Comprehensive Cancer Network, Inc. Available at: <http://www.nccn.org>. Accessed on October 14, 2020. Search term: mechlorethamine.
3. The NCCN Primary Cutaneous Lymphomas Clinical Practice Guidelines in Oncology (Version 1.2021 – October 12, 2020). © 2020 National Comprehensive Cancer Network, Inc. Available at: <http://www.nccn.org>. Accessed on October 14, 2020.
4. The NCCN T-Cell Lymphomas Clinical Practice Guidelines in Oncology (Version 1.2021 – October 5, 2020). © 2020 National Comprehensive Cancer Network, Inc. Available at: <http://www.nccn.org>. Accessed on October 14, 2020.